• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Consensus on MRD in AML?

作者信息

Paietta Elisabeth

机构信息

Montefiore Medical Center.

出版信息

Blood. 2018 Mar 22;131(12):1265-1266. doi: 10.1182/blood-2018-01-828145.

DOI:10.1182/blood-2018-01-828145
PMID:29567752
Abstract
摘要

相似文献

1
Consensus on MRD in AML?急性髓系白血病微小残留病的共识？
Blood. 2018 Mar 22;131(12):1265-1266. doi: 10.1182/blood-2018-01-828145.
2
When it comes to MRD, AML ≠ ALL.说到微小残留病灶（MRD），急性髓系白血病（AML）≠急性淋巴细胞白血病（ALL）。
Blood. 2012 Aug 23;120(8):1536-7. doi: 10.1182/blood-2012-06-435081.
3
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.流式细胞术微小残留病检测对急性髓系白血病具有高度预后影响：HOVON/SAKK AML 42A 研究数据。
J Clin Oncol. 2013 Nov 1;31(31):3889-97. doi: 10.1200/JCO.2012.45.9628. Epub 2013 Sep 23.
4
Minimal/Measurable Residual Disease Monitoring in -Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives.伴有突变的急性髓系白血病中的微小残留病监测：临床观点和展望。
Int J Mol Sci. 2018 Nov 6;19(11):3492. doi: 10.3390/ijms19113492.
5
High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.WT1基因表达检测在细胞完全缓解后接受异基因干细胞移植的急性髓系白血病患者中对移植前微小残留病检测具有较高的预后价值。
Leuk Res. 2017 Dec;63:22-27. doi: 10.1016/j.leukres.2017.10.010. Epub 2017 Oct 27.
6
Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.急性髓系白血病的最佳可测量残留病检测
Surg Pathol Clin. 2019 Sep;12(3):671-686. doi: 10.1016/j.path.2019.03.009. Epub 2019 May 18.
7
Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.儿童急性髓细胞白血病复发和生存的预测因素：微小残留病的作用。
Expert Rev Anticancer Ther. 2011 Sep;11(9):1391-401. doi: 10.1586/era.11.37.
8
Methods of Detection of Measurable Residual Disease in AML.急性髓系白血病中可测量残留病的检测方法
Curr Hematol Malig Rep. 2017 Dec;12(6):557-567. doi: 10.1007/s11899-017-0419-5.
9
Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study.干扰素-α 对异基因造血干细胞移植后 t(8;21) 急性髓系白血病患者微小残留病的治疗有效：一项前瞻性登记研究的结果。
Oncologist. 2018 Nov;23(11):1349-1357. doi: 10.1634/theoncologist.2017-0692. Epub 2018 Aug 3.
10
Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.可测量残留疾病、调理方案强度和年龄可预测首次缓解的急性髓系白血病患者接受异基因造血细胞移植的结果：欧洲血液和骨髓移植学会急性白血病工作组对 2292 例患者的注册分析。
Am J Hematol. 2018 Sep;93(9):1142-1152. doi: 10.1002/ajh.25211. Epub 2018 Aug 15.

引用本文的文献

1
Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts.急性髓细胞白血病中的微小残留病：旧概念与新概念。
Int J Mol Sci. 2024 Feb 10;25(4):2150. doi: 10.3390/ijms25042150.
2
Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML.作为 AML 疗效反应替代生物标志物的可测量残留疾病（MRD）。
Int J Mol Sci. 2023 Feb 4;24(4):3062. doi: 10.3390/ijms24043062.
3
MRD Monitoring by Multiparametric Flow Cytometry in AML: Is It Time to Incorporate Immune Parameters?急性髓系白血病中通过多参数流式细胞术进行微小残留病监测：是时候纳入免疫参数了吗？
Cancers (Basel). 2022 Sep 1;14(17):4294. doi: 10.3390/cancers14174294.
4
Inhibiting autophagy targets human leukemic stem cells and hypoxic AML blasts by disrupting mitochondrial homeostasis.通过破坏线粒体稳态，抑制自噬靶向人白血病干细胞和低氧 AML 原始细胞。
Blood Adv. 2021 Apr 27;5(8):2087-2100. doi: 10.1182/bloodadvances.2020002666.
5
Dendritic Cells of Leukemic Origin: Specialized Antigen-Presenting Cells as Potential Treatment Tools for Patients with Myeloid Leukemia.白血病源性树突状细胞：作为髓系白血病患者潜在治疗工具的特殊抗原呈递细胞
Transfus Med Hemother. 2020 Dec;47(6):432-443. doi: 10.1159/000512452. Epub 2020 Nov 5.
6
The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles.急性髓系白血病从初次诊断到化疗耐药复发的进展：蛋白质组学和磷酸化蛋白质组学图谱比较
Cancers (Basel). 2020 Jun 4;12(6):1466. doi: 10.3390/cancers12061466.
7
Measurable Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry: A Review of Where We Are and Where We Are Going.流式细胞术检测急性髓系白血病微小残留病：现状与展望综述
J Clin Med. 2020 Jun 3;9(6):1714. doi: 10.3390/jcm9061714.
8
Clustering and Kernel Density Estimation for Assessment of Measurable Residual Disease by Flow Cytometry.用于通过流式细胞术评估可测量残留病的聚类和核密度估计
Diagnostics (Basel). 2020 May 18;10(5):317. doi: 10.3390/diagnostics10050317.
9
Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies.急性髓系白血病患儿微小残留病的流式细胞术监测：最新进展与未来策略
Front Pediatr. 2019 Oct 11;7:412. doi: 10.3389/fped.2019.00412. eCollection 2019.
10
MRD in AML: The Role of New Techniques.急性髓系白血病中的微小残留病：新技术的作用
Front Oncol. 2019 Jul 23;9:655. doi: 10.3389/fonc.2019.00655. eCollection 2019.